Christopher Coleclough is a notable inventor based in Germantown, TN (US). He has made significant contributions to the field of viral vaccine development, particularly in relation to human immunodeficiency viruses (HIV). With a total of 2 patents, his work is paving the way for innovative approaches to vaccine technology.

Latest Patents

Coleclough's latest patents focus on the preparation and use of viral vectors for mixed envelope protein vaccines against HIV. His polyenv vaccines comprise mixtures of at least 4 to about 10,000 different recombinant viruses, each expressing a different HIV envelope variant. These vaccines include both constant and variable regions, and they are designed for use in live, attenuated, or inactivated forms for the prophylaxis or treatment of HIV infection. The invention also emphasizes the optimal combination of these viral vaccines with a recombinant HIV envelope booster or a recombinant HIV envelope gene DNA priming or boosting vaccine.

Career Highlights

Christopher Coleclough is currently affiliated with St. Jude Children's Research Hospital, where he continues to advance his research in viral vaccines. His work is critical in the ongoing fight against HIV, contributing to the development of effective treatment and prevention strategies.

Collaborations

Throughout his career, Coleclough has collaborated with esteemed colleagues such as Julia Lea Hurwitz and Randall Owens. These partnerships have enhanced the scope and impact of his research efforts.

Conclusion

Christopher Coleclough is a dedicated inventor whose work in viral vaccine development is making a significant impact in the medical field. His innovative approaches to combating HIV through advanced vaccine technology are crucial for future advancements in public health.